Bayer follows R&D deal spree by raiding Roche's cancer group for its new research chief
The day after Bayer signed off on a $4 billion deal designed to put the company among the leaders in gene therapy development, the pharma giant has recruited a new chief for its R&D division. And they opted for an expert in the cancer field.
Christian Rommel, Roche’s head of discovery and early-stage oncology development, has been tapped to take over the job. Joerg Moeller, who got the top research post after early- and late-stage development roles were combined 2 years ago, is hitting the exit “to pursue other career opportunities.”
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 94,300+ biopharma pros reading Endpoints daily — and it's free.